Comparable stake leader
Deep Track Capital, LP
SEC ownership of LB PHARMACEUTICALS INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001691082.
Disclosed value leader
Deep Track Capital, LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- LBRX on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Deep Track Capital, LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Deep Track Capital, LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001691082
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of LB PHARMACEUTICALS INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Deep Track Capital, LP
Disclosed value leader
Deep Track Capital, LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 15%
13D/G row: Deep Track Capital, LP
Showing 1-8 of 50 holder rows.
Quick read
Deep Track Capital, LP leads the comparable SEC ownership view at 15%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Deep Track Capital, LP's linked filing trail.
Comparable ownership
Top 5
Deep Track Capital, LP
15%
RA CAPITAL MANAGEMENT, L.P.
8.7%
Commodore Capital LP
6.8%
TCG Crossover GP II, LLC
6.4%
BlackRock, Inc.
6.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Deep Track Capital, LP |
13F
13D/G
Company
|
15%
from 13D/G
|
$82,680,147
3,352,804 shares
|
— | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
8.7%
from 13D/G
|
$54,464,175
2,208,604 shares
|
— | 31 Mar 2026 |
| Commodore Capital LP |
13D/G
13F
Company
|
6.8%
|
$48,007,461
1,972,369 shares
|
+$18,190,961 | 31 Mar 2026 |
| TCG Crossover GP II, LLC |
13D/G
|
6.4%
|
$44,773,162
1,839,489 shares
|
+$2,299,497 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.3%
from 13D/G
|
$60,931,038
2,470,845 shares
|
— | 31 Mar 2026 |
| Pontifax Management 4 G.P. (2015) Ltd. |
3/4/5
13D/G
10%+ Owner
|
6.3%
from 13D/G
|
—
1,411,681 shares
|
— | 12 Sep 2025 |
| JPMORGAN CHASE & CO |
13D/G
13F
Company
|
5.2%
|
$48,594,644
1,497,293 shares
|
+$2,262,925 | 30 Jun 2026 |
| Caligan Partners LP |
13D/G
13F
Company
|
5%
|
$35,002,624
1,438,070 shares
|
$0 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$10,000,004.
Buys
$10,000,004
Insiders: 1
Sells
$0
Insiders: 0
Net
+$10,000,004
Shares: +472,369
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 472,369
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 472,369 | 0 | $10,000,004 | $0 | +$10,000,004 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to LB PHARMACEUTICALS INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Deep Track Biotechnology Master Fund, Ltd.
Net 12M change
+$10,000,004
Latest report
03 Jun 2026
Recent insider transactions for LB PHARMACEUTICALS INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Robert R. Ruffolo | LBRX | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 03 Jun 2026 | Direct | |||
| Ran Nussbaum | LBRX | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 03 Jun 2026 | Direct | |||
| Rebecca Luse | LBRX | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 03 Jun 2026 | Direct | |||
| Robert A. Lenz | LBRX | Stock Option (Right to Buy) | Award | 12,500 | 12,500 | 03 Jun 2026 | Direct | |||
| Rekha Hemrajani | LBRX | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 03 Jun 2026 | Direct | |||
| William P. Kane Jr. | LBRX | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 03 Jun 2026 | Direct | |||
| J. Scott Garland | LBRX | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 03 Jun 2026 | Direct | |||
| Robert A. Lenz | LBRX | Stock Option (Right to Buy) | Award | 20,000 | 20,000 | 06 Mar 2026 | Direct | |||
| Deep Track Biotechnology Master Fund, Ltd. | LBRX | Pre-Funded Warrants (Right to Buy) | Purchase | $1,988,383 | $21.17 | 93,925 | 93,925 | 06 Feb 2026 | By Deep Track Special Opportunities Fund, LP | |
| Deep Track Biotechnology Master Fund, Ltd. | LBRX | Pre-Funded Warrants (Right to Buy) | Purchase | $8,011,622 | $21.17 | 378,444 | 378,444 | 06 Feb 2026 | Direct | |
| Panandiker Kaya Kamlesh Pai | Employee Stock Option (Right to Buy) | Award | 195,000 | 195,000 | 10 Dec 2025 | Direct | ||||
| Deep Track Biotechnology Master Fund, Ltd. | Common Stock | Purchase | 666,666 | 666,666 | 12 Sep 2025 | By Deep Track Special Opportunities Fund, LP | ||||
| Deep Track Biotechnology Master Fund, Ltd. | Common Stock | Purchase | 291.5% | 2,000,000 | 2,686,138 | 12 Sep 2025 | Direct | |||
| Deep Track Biotechnology Master Fund, Ltd. | Common Stock | Conversion of derivative security | 686,138 | 686,138 | 12 Sep 2025 | Direct | ||||
| Deep Track Biotechnology Master Fund, Ltd. | Series C Preferred Stock | Conversion of derivative security | -100% | -16,666,667 | 0 | 12 Sep 2025 | Direct | |||
| Pontifax Management 4 G.P. (2015) Ltd. | Common Stock | Purchase | 242.9% | 1,000,000 | 1,411,681 | 12 Sep 2025 | See footnote | |||
| Pontifax Management 4 G.P. (2015) Ltd. | Common Stock | Conversion of derivative security | 411,681 | 411,681 | 12 Sep 2025 | See footnote | ||||
| Pontifax Management 4 G.P. (2015) Ltd. | Series C Preferred Stock | Conversion of derivative security | -100% | -10,000,000 | 0 | 12 Sep 2025 | See footnotes | |||
| Ran Nussbaum | Common Stock | Purchase | 242.9% | 1,000,000 | 1,411,681 | 12 Sep 2025 | See footnote | |||
| Ran Nussbaum | Common Stock | Conversion of derivative security | 411,681 | 411,681 | 12 Sep 2025 | See footnote | ||||
| Ran Nussbaum | Series C Preferred Stock | Conversion of derivative security | -100% | -10,000,000 | 0 | 12 Sep 2025 | See footnotes | |||
| Vida Ventures GP III, L.L.C. | Common Stock | Purchase | 60.8% | 767 | 2,029 | 12 Sep 2025 | By Vida Ventures III-A, L.P. | |||
| Vida Ventures GP III, L.L.C. | Common Stock | Purchase | 60.7% | 332,566 | 880,214 | 12 Sep 2025 | By Vida Ventures III, L.P. | |||
| Vida Ventures GP III, L.L.C. | Common Stock | Conversion of derivative security | 1,262 | 1,262 | 12 Sep 2025 | By Vida Ventures III-A, L.P. | ||||
| Vida Ventures GP III, L.L.C. | Common Stock | Conversion of derivative security | 547,648 | 547,648 | 12 Sep 2025 | By Vida Ventures III, L.P. | ||||
| Vida Ventures GP III, L.L.C. | Series C Preferred Stock | Conversion of derivative security | -100% | -30,667 | 0 | 12 Sep 2025 | By Vida Ventures III-A, L.P. | |||
| Vida Ventures GP III, L.L.C. | Series C Preferred Stock | Conversion of derivative security | -100% | -13,302,666 | 0 | 12 Sep 2025 | By Vida Ventures III, L.P. | |||
| Marc L. Panoff | Employee Stock Option (Right to Buy) | Award | 118,134 | 90,525 | 10 Sep 2025 | Direct | ||||
| Marc L. Panoff | Employee Stock Option (Right to Buy) | Disposed to Issuer | -100% | -27,609 | 0 | 10 Sep 2025 | Direct | |||
| Rekha Hemrajani | Stock Option (Right to Buy) | Award | 22,449 | 22,449 | 10 Sep 2025 | Direct | ||||
| Rebecca Luse | Stock Option (Right to Buy) | Award | 22,449 | 22,449 | 10 Sep 2025 | Direct | ||||
| William P. Kane Jr. | Stock Option (Right to Buy) | Award | 22,449 | 22,449 | 10 Sep 2025 | Direct | ||||
| Robert R. Ruffolo | Stock Option (Right to Buy) | Award | 35,715 | 22,449 | 10 Sep 2025 | Direct | ||||
| Robert R. Ruffolo | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -13,266 | 0 | 10 Sep 2025 | Direct | |||
| Zachary Prensky | Stock Option (Right to Buy) | Award | 100,260 | 53,787 | 10 Sep 2025 | Direct | ||||
| Zachary Prensky | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -77,811 | 0 | 10 Sep 2025 | Direct | |||
| Ran Nussbaum | Stock Option (Right to Buy) | Award | 22,449 | 22,449 | 10 Sep 2025 | Direct | ||||
| J. Scott Garland | Employee Stock Option (Right to Buy) | Award | 43,963 | 22,449 | 10 Sep 2025 | Direct | ||||
| J. Scott Garland | Employee Stock Option (Right to Buy) | Disposed to Issuer | -100% | -21,514 | 0 | 10 Sep 2025 | Direct | |||
| Richard Anthony Silva | Employee Stock Option (Right to Buy) | Award | 89,863 | 80,899 | 10 Sep 2025 | Direct | ||||
| Richard Anthony Silva | Employee Stock Option (Right to Buy) | Disposed to Issuer | -100% | -8,964 | 0 | 10 Sep 2025 | Direct | |||
| Anna Eramo | Employee Stock Option (Right to Buy) | Award | 188,980 | 155,812 | 10 Sep 2025 | Direct | ||||
| Anna Eramo | Employee Stock Option (Right to Buy) | Disposed to Issuer | -100% | -33,168 | 0 | 10 Sep 2025 | Direct | |||
| Gad Soffer | Employee Stock Option (Right to Buy) | Award | 256,753 | 229,860 | 10 Sep 2025 | Direct | ||||
| Gad Soffer | Employee Stock Option (Right to Buy) | Disposed to Issuer | -100% | -26,893 | 0 | 10 Sep 2025 | Direct | |||
| Heather D. Turner | Employee Stock Option (Right to Buy) | Award | 1,155,391 | 971,828 | 10 Sep 2025 | Direct | ||||
| Heather D. Turner | Employee Stock Option (Right to Buy) | Disposed to Issuer | -100% | -183,563 | 0 | 10 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.